Cancer cells reveal their electrical vulnerability

Physician Raymond Damadian discovered in 1971 that cancer cells possess a distinct electrical signature compared to healthy tissue. He observed that these cells are electrically depolarized, carrying a lower charge, which coincides with a breakdown in the organization of intracellular water molecules (Why Does My Body Do That?). This specific finding led Damadian to develop the MRI, a tool designed to detect the structural state of water within tissue rather than just capturing simple images. The discovery implies that the therapeutic efficacy of certain drugs may rely on their capacity to alter this internal water state.

Taxol, a chemotherapy agent derived from the Pacific yew tree, disrupts microtubules—the internal scaffolding that organizes structured water—to halt cell division. Researchers confirmed this mechanism in 1979, establishing that by breaking the cellular scaffold, the drug forces a transition in the cell's water state. Similar effects appear in other compounds; a $2 antiparasitic drug targets the same microtubule pathways as taxol, which generates over $1.6 billion in annual revenue for breast, ovarian, and lung cancer treatments. These findings suggest that modulating microtubule function remains a viable area for research into cellular electrical health (Why Does My Body Do That?).